Melinta Therapeutics Announces Successful Completion of Merger

New Nasdaq-Listed Melinta Therapeutics Will Begin Trading on November 6, 2017 under Ticker MLNT

Melinta Therapeutics Inc. (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial infections, announced that the company’s merger with Cempra, Inc. has closed. Melinta Therapeutics will commence trading on November 6, 2017 on the NASDAQ Global Market under the symbol “MLNT.”